Research Progress of Fruquintinib on Advanced Colorectal Cancer / 肿瘤防治研究
Cancer Research on Prevention and Treatment
; (12): 1135-1142, 2021.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-988469
Responsible library:
WPRO
ABSTRACT
Fruquintinib is an effective, highly selective and oral VEGFR 1, 2 and 3 tyrosine kinase inhibitor. It was discovered and developed by Hutchison MediPharma for the treatment of solid tumors. In September 2018, fruquintinib received its first global approval in China for use in the treatment of metastatic colorectal cancer (CRC) patients who have failed at least two prior systemic anti-neoplastic therapies. Clinical studies have shown that it has the advantages of low off-target toxicity, good drug resistance and strong curative effect. This article reviews the molecular structure, mechanism of action, pharmacokinetics, clinical efficacy and safety of fruquintinib, as well as its potential clinical applications in other tumor types.
Full text:
Available
Database:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Cancer Research on Prevention and Treatment
Year:
2021
Document type:
Article